Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Increases Price Target for Procter Gamble Expresses Positive Outlook

Elaine Mendonca by Elaine Mendonca
January 24, 2024
in Breaking News
0
Consumer Electronics Stock Market Today
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

As of January 24, 2024, Raymond James analyst Olivia Tong has expressed her positive stance on Procter & Gamble (NYSE:PG) by maintaining an Outperform rating and increasing the price target from $170 to $175. This revision indicates her optimistic outlook for the company’s stock performance. It is noteworthy that the overall rating for Procter & Gamble is also reported to be Outperform, with analysts’ price targets ranging between $138 and $178. This adjustment in the price target further reinforces the analysts’ confidence in the company’s future prospects.

Procter & Gamble (PG) Stock Performance Shows Promising Signs on January 24, 2024

Procter & Gamble (PG) has shown promising signs in its stock performance on January 24, 2024. PG is currently trading near the top of its 52-week range and above its 200-day simple moving average, indicating positive price momentum. The recent increase in the price of PG shares, reflecting a 4.14% rise, is encouraging for investors. Despite a slight drop in pre-market trading, the overall upward trend suggests potential for recovery and continued positive trajectory throughout the day. Trading near its 52-week high and above its 200-day moving average are bullish signals, indicating strong financials and positive market sentiment. Overall, PG’s stock performance on January 24, 2024, appears promising, but investors should continue to monitor its performance throughout the day.

Procter & Gamble (PG) Stock Performance: Flat Revenue but Decrease in Net Income and EPS during Second Quarter

Procter & Gamble (PG) reported its stock performance on January 24, 2024. The total revenue for the past year remained flat at $82.01 billion compared to the previous year. Similarly, the total revenue for the second quarter held steady at $21.44 billion. However, the net income figures showed some fluctuations. The net income for the past year remained flat at $14.65 billion, but during the second quarter, it decreased by 23.29% to $3.47 billion. The earnings per share (EPS) for the past year held flat at $5.90, but during the second quarter, it decreased by 23.08% to $1.41. These declines in net income and EPS indicate a decrease in profitability during the second quarter. Investors and analysts will closely monitor these figures to assess the company’s ability to maintain sustainable growth.

Tags: PG
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Abbott Laboratories Reports Strong FourthQuarter Financial Performance

Finance_Investment (2)

Notable Insider Sales and Their Importance in Investment Decisions

Aerospace and Defense Trading online (1)

Lockheed Martin and Red 6 Announce Strategic Collaboration for Innovation and Growth in Aerospace

Recommended

Jakks Pacific Reports Disappointing Q4 2023 Earnings

2 years ago
Ecommerce Stock Exchange

Notable Options Market Activity for Shopify

2 years ago
Fannie Mae Stock

Fannie Mae’s Public Offering Plans Derailed by Prominent Investor

3 months ago
Ocugen Stock

Ocugen Shares Face Critical Test Amid Steep Decline

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

TCG BDC Investors Await Key Financial Milestones

Trending

Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

by Rodolfo Hanigan
February 7, 2026
0

Investors in Viking Therapeutics are currently focused on a specific calendar event rather than breaking news. The...

Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment
  • Diginex Enters Critical Implementation Phase Following Strategic Moves
  • Deluxe Stock Gains Momentum on Successful Fintech Transition

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com